Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - TANDEM DIABETES CARE INC | tndm-ex991_6.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 21, 2016
Tandem Diabetes Care, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-36189 |
|
20-4327508 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer |
|
11045 Roselle Street, San Diego, CA |
|
92121 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (858) 366-6900
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On July 21, 2016, we issued a press release announcing that we have entered into a License Agreement with TypeZero Technologies, LLC (the “Agreement”), which allows us to integrate TypeZero’s artificial pancreas (“AP”) technology into a next-generation t:slim® Insulin Pump. The terms of the Agreement between Tandem and TypeZero include a worldwide, non-exclusive license for the use of TypeZero’s AP technology in future Tandem products. The Agreement also provides Tandem access to TypeZero’s future AP innovations over the next five years. Financial details of the Agreement have not been disclosed.
The press release announcing the Agreement is attached hereto as Exhibit 99.1 and is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press release of Tandem Diabetes Care, Inc. dated July 21, 2016. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Tandem Diabetes Care, Inc. |
|
|
|
|
|
Date: July 21, 2016 |
|
/s/ David B. Berger |
|
|
|
David B. Berger |
|
|
|
Executive Vice President, General Counsel and Secretary |
|
Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press release of Tandem Diabetes Care, Inc. dated July 21, 2016. |